- Gene Signal International, a Biotech Company Registered in
Switzerland, Will Move its Headquarter to the EPFL, in Lausanne,
- Gene Signal is Addressing Various Issues Related to Neovascularisation,
- Gene Signal is Working on a Portfolio of Ophthalmologic Indications,
With One Now in Phase III Trials
- Gene Signal Will Present its Interim Results at the Annual Meeting of
the American Academy of Ophtalmologist in Atlanta, USA, the
Largest Scientific Convention in this Field
Gene Signal, a biotech company registered in Switzerland, is currently starting the Phase III study of GS-101, its most advanced therapeutic ophthalmic solution, for the prevention of corneal graft rejection.
Every year, over 40'000 corneal grafts are performed worldwide to cure or prevent blindness, thus making this procedure the most frequently performed transplant surgery. However, the 5 year failure rate for corneal grafts is currently around 35%. As many other graft procedures, donor grafts are always in limited supply. A failure is even more "wasteful" in this context of long waiting lines (6 months - 2 years).
One of the main reasons for graft failure is the immune response of the body. Normally, the cornea is avascular (i.e. deprived of blood vessels), protecting the donor cornea from being rejected. However, under certain circumstances, new blood vessel creation (neovascularization) occurs, inducing an immune response to the donor graft that can lead to immunological corneal graft rejection.
Currently, there is no therapy available. Gene Signal is working on new ways to prevent this syndrome. With its antisense oligonucleotide approach, it aims to block the pathways leading to the formation of blood vessels in the cornea. This approach uses short DNA fragments that specifically target and block the production of a protein that is required for the formation and growth of new blood vessels.<
|SOURCE Gene Signal International SA|
Copyright©2008 PR Newswire.
All rights reserved